In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AVE STOCK CLIMBS 13% IN JANUARY ON COMPANY PRODUCT APPROVALS, STRONG WORLDWIDE CORONARY STENT MARKET OUTLOOK; O-T-C INDEX COMPOSITE UP 3.2%

This article was originally published in The Gray Sheet

Executive Summary

Arterial Vascular Engineering stock's January debut on "The Gray Sheet" Index coincided with a solid 8-1/2 point (13.1%) run-up during the month to 73-1/2. Investor enthusiasm for the issue, roused by the Dec. 23 approval of the company's Micro Stent II and GFX coronary stent systems, was heightened further by Wall Street predictions of "explosive" stent market growth in 1998.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel